Results of the CheckMate 651 study: comparing treatment outcomes of first-line nivolumab and ipilimumab with EXTREME regimen for recurrent/metastatic squamous cell carcinoma of the head and neck
In this medfyle
First-line nivolumab plus ipilimumab did not result in a significant improvement in OS versus the EXTREME regimen when administered as first-line treatment for patients with recurrent/metastatic SCCHN.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
©Copyright Medfyle 2023
Original article:
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. PMID: 36473143; PMCID: PMC10115555.
The summary content was prepared by by Louise Gardner for Medfyle, and reviewed by Marianna Aita, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
